BioAegis Therapeutics, Inc. will present to investors at the Marcum Microcap Conference on June 15, 2017. This conference is a nationally recognized forum for private and publicly traded companies with less than $500 million in market capitalization to network with fund managers and high net worth investors who focus on small cap equities. It draws over 2000 participants from the microcap community. BioAegis CEO, Susan Levinson, PhD, will be presenting.
When: Thursday, June 15, 2017, 4 PM
Where: Winter Garden Room, Grand Hyatt New York, New York, NY.

BioAegis Therapeutics, Inc. will present at the Cavendish Global Health Impact Forum in Washington, DC. on May 8, 2017. BioAegis’ technology was chosen as one of the groundbreaking discoveries and innovations at a program billed as “United for Impact: A Multi-sector Collaboration to Transform Health and Lifesciences.” Cavendish brings together participants that “share a passion for well-conceived impact investing, sustainable philanthropy and delivering transformative impact.”

Markers of Acute Kidney Injury to be Monitored in Forthcoming Clinical Trials

BOSTON, MA and MORRISTOWN, NJ, (BIOAEGIS THERAPEUTICS) February 27, 2017 BioAegis Therapeutics Inc., a privately held biotechnology company exploiting plasma gelsolin’s (pGSN) role in immune function announced that it has expanded its clinical advisory board to include John Kellum, MD–noted critical care physician and acute kidney injury expert at the University of Pittsburgh Medical Center.

John Kellum, M.D. is a clinician scientist whose research interests span various aspects of Critical Care Medicine, but center in critical care nephrology (including acid-base, and renal replacement therapy), sepsis and multi-organ failure (including blood purification), and clinical epidemiology. His research has received continuous funding from the National Institutes of Health since 2001, and he has active funding from multiple different NIH Institutes. Dr. Kellum has authored more than 300 publications and has also edited several major textbooks including Critical Care Nephrology and Stewart’s Textbook of Acid-Base.

Read the full press release here:John Kellum Clinical Advisor

New Patents Issued Across Multiple Geographies in US, Japan and Canada

BOSTON, MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – December, 2016) BioAegis Therapeutics announces that
during 2016 its patent portfolio expanded globally in multiple indications. The newly issued patents extend coverage in infectious disease, neurological disease and renal failure. The plasma gelsolin portfolio now includes more than 20 issued patents and many pending applications.

BioAegis Therapeutics announced that it has completed two successful manufacturing runs to produce lyophilized clinical supplies of plasma gelsolin. The drug product in this formulation has already been found to be highly temperature-stable in over two years of stability studies, which are ongoing. The lypophilization of biologics is utilized to eliminate the necessity of cold-chain storage, facilitating use in the clinic and minimizing storage and shipping costs.